Ideaya Biosciences (IDYA) announced that it has entered into a clinical trial collaboration and supply agreement with Merck (MRK) to evaluate IDE161, the company’s investigational, potential first-in-class, small molecule poly glycohydrolase, or PARG, inhibitor, in combination with Keytruda Merck’s anti-PD-1 therapy, in patients with microsatellite instability-, or MSI-, high and microsatellite stable, or MSS, endometrial cancer, in a Phase 1 clinical trial.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IDYA:
- GE upgraded, Vail Resorts downgraded: Wall Street’s top analyst calls
- Ideaya Biosciences initiated with a Buy at BTIG
- Ideaya Biosciences price target raised to $53 from $43 at RBC Capital
- Ideaya Biosciences price target raised to $50 from $40 at Oppenheimer
- Ideaya Biosciences reports Q4 EPS (52c), consensus (47c)